Premium
The use of colony stimulating factors in marrow transplantation
Author(s) -
Appelbaum Frederick R.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19931201)72:11+<3387::aid-cncr2820721605>3.0.co;2-g
Subject(s) - medicine , granulocyte , granulocyte macrophage colony stimulating factor , granulocyte colony stimulating factor , transplantation , haematopoiesis , colony stimulating factor , immunology , progenitor cell , stem cell , cytokine , chemotherapy , biology , genetics
Colony stimulating factors (CSF) are now widely used in marrow transplantation. Randomized trials have shown that granulocyte macrophage‐CSF accelerates marrow recovery after autologous marrow transplantation, resulting in fewer infections, shorter hospitalization, and lower costs. Similar results have been seen with granulocyte‐CSF. Both factors also can accelerate engraftment after allogenic marrow transplantation, but there is, so far, less evidence for clinical benefit in this setting. Both granulocyte macrophage‐CSF and granulocyte‐CSF benefit some patients with graft failure. The recent demonstration that both granulocyte‐CSF and granulocyte macrophage‐CSF can mobilize large numbers of hematopoietic stem cells into peripheral blood has resulted in the wide‐spread use of this technique as an alternative to autologous marrow transplantation. A number of colony stimulating factors, including IL‐1, IL‐3, and steel factor, which act on early hematopoietic progenitors, have recently been entered into clinical trials, with the hope that the progress already made with G‐CSF and GM‐CSF can be continued.